A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Ixekizumab

Criteria

Inclusion Criteria:

• Present with chronic moderate-to-severe plaque psoriasis based on a confirmed (by a dermatologist) diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline

• Active psoriatic skin lesions of plaque psoriasis (Ps)

• Are a candidate for phototherapy and/or systemic therapy

• Men must agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

• Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion Criteria:

• Are unable to commit to the photography schedule for the duration of the study

• Have participated in any study with interleukin 17 (IL-17) or (IL-23) antagonists, including ixekizumab

• Serious disorder or illness other than psoriasis

• Serious infection within the last 3 months

• Breastfeeding or nursing (lactating) women